Pros and cons of DPP-IV-Inhibitor for pneumonia in the elder

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K07923
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Kyorin University
• Principal Investigator: Ebihara Takae 杏林大学, 医学部, 准教授 (30396478)
• Co-Investigator(Kenkyū-buntansha): 神崎 恒一 杏林大学, 医学部, 教授 (80272540) ; 永井 久美子 杏林大学, 医学部, その他 (60398592)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: pneumonia / aspiration / dpp-iv-inhibitor

Outline of Final Research Achievements

DPP-IV inhibitors are very beneficial in terms of cognitive function and blood glucose control in dementia patients with diabetics. However, the effectiveness of oral DPP-IV inhibitors in preventing pneumonia in diabetic patients is unclear. DPP-IV inhibitors may attenuate CD26 T cell activation, while DPP-IV inhibitors has the effect of preventing substance P inactivation, so it may be possible to prevent "aspiration". In this study, the DPP-IV inhibitors group tended to develop pneumonia more frequently than the non-DPP-IV inhibitors group. The mechanism of pneumonia development is different from the previous mechanism of pneumonia development caused by weakening the dopaminergic nervous system and the lower SP nervous system, and DPP-IV inhibitors substances are thought to be a mechanism of pneumonia susceptibility by inhibiting SP inactivation and attenuating incretin hormone activation and T cell activation.

Free Research Field

誤嚥性肺炎

Academic Significance and Societal Importance of the Research Achievements

DPP-IV阻害剤の免疫に関する脆弱性が相次いで報告されている。認知機能と血糖コントロールの観点からは非常に有益な薬剤であるが、低免疫状態で、誤嚥性肺炎リスク群にある要介護高齢者へのDPP-IV阻害剤の安易な使用に警鐘を鳴らす。